Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Am J Kidney Dis. 2008 Dec 19;53(3):426–437. doi: 10.1053/j.ajkd.2008.09.024

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

Higher performing hospitals were found to have higher rates of prescribing for each of the 5 guideline-recommended acute medications: aspirin (1a), β-blocker (1b), clopidogrel (1c), heparin (1d), and GP IIb/IIIa inhibitors (1e). An eGFR effect was present in both the leading and lagging hospital rank groups for GPIIb/IIIa inhibitors (1e) indicating that there was a decrease in use of this medication across the spectrum of eGFR while no eGFR effect was present in either rank groups for β-blocker and heparin therapies (1b, 1d), indicating that prescribing rates for this medication do not vary according to eGFR across hospitals of all quality ranks. For the other therapies (1a, 1c), an eGFR effect was present in the leading but not the lagging hospital rank groups.